Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ASTRAZEN.NS
SellFallen FavouriteAstraZeneca Pharma India Limited · Healthcare · India · $1.8B · Avg Vol: $1M/d
30
StockRankGet insider-trade alerts
Q
66
V
14
M
39
P/E (TTM)
101.0x
ROE
21.5%
D/E
0.1x
Dividend %
0.5%
COMPANY DESCRIPTION
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 10.0B | 13.0B | 17.1B | 22.7B | 31.3% | 24.4B |
| EPS (INR) | 39.70 | 64.60 | 46.30 | 75.00 | 23.6% | 68.30 |
| Shares | 25.0M | 25.0M | 25.0M | 25.0M | 0.0% | 25.0M |
| Debt | 72.1M | 45.9M | 357.3M | 1.1B | 148.5% | 1.1B |
| Equity | 5.9B | 7.1B | 7.7B | 8.7B | 14.0% | — |
| Op CF | 582.9M | 278.7M | 653.6M | -151.4M | 5.9% | -151.9M |
| Inv CF | 181.1M | 217.4M | 308.0M | 186.9M | — | — |
| Fin CF | -244.8M | -443.8M | -655.9M | -919.7M | — | — |
Loading 1Y...
PRICE (1Y)-15.6%
SMA 50SMA 200
Close
$72.06
RSI (14)
11.2
52W High
$102.75
From 52W High
0.7%
SCORE BREAKDOWN
Quality
66
ROIC
23.2%93.0
ROE
21.5%89.8
GP/Assets
45.0%82.5
Op. Margin
6.4%55.5
FCF/Assets
-0.9%42.9
Piotroski
431.0
Int. Cover
40.9x77.0
D/E Ratio
0.13x59.0
Current Ratio
1.77x33.8
Value
14
P/E (TTM)
101.0x8.8
EV/EBITDA
74.7x7.1
P/FCF
—N/A
P/B
19.7x5.8
P/S
7.1x33.1
Div Yield
0.5%16.4
Momentum
39
52W High %
70%49.3
RS 6M
-17%42.5
SMA 50/200
0.93x38.1
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
-32%16.3
FUNDAMENTALS
Market Cap
$1.8B
P/E (Forward)
—
Gross Margin
36.8%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ASTRAZEN.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ASTRAZEN.NS | AstraZeneca Pharma India Limited(you) | $1.8B | 30 | Sell |
| COHANCE.NS | Cohance Lifesciences Limited | $1.8B | 37 | Hold |
| SUDEEPPHRM.NS | Sudeep Pharma Limited | $1.6B | 41 | Hold |
| SUVEN.NS | Suven Life Sciences Limited | $1.1B | 34 | Sell |
| ERIS.NS | Eris Lifesciences Limited | $1.9B | 55 | Hold |
| NOVARTIND.NS | Novartis India Limited | $475M | 30 | Sell |
| JUBLPHARMA.NS | Jubilant Pharmova Limited | $1.7B | 60 | Hold |
| WOCKPHARMA.NS | Wockhardt Limited | $3.8B | 54 | Hold |
| RDY | Dr. Reddy's Laboratories Limited | $10.1B | 34 | Sell |
| PPLPHARMA.NS | Piramal Pharma Limited | $3.2B | 58 | Hold |
Peer medians: ROE 11.8% · P/E 42.5x · Gross margin 59.4%